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Introduction: In this report, we describe a rare case of papillary thyroid carcinoma with adrenocortical carcinoma
without excess hormone production.
Case presentation: A 40-year-old Turkish man was admitted to our institution with a large left adrenal mass that
was identified during the work-up for shortness of breath. The patient did not have specific signs and symptoms of
hormone excess. The mass was removed surgically. The pathological findings were consistent with adrenocortical
carcinoma. The patient was also found to have a multicentric papillary thyroid microcarcinoma.
Conclusion: Most adrenocortical carcinomas and papillary thyroid carcinomas are sporadic; however, the
occurrence of two different endocrine neoplasms during the same period of time is a rare situation, but it is
possible, as in our patient. When an endocrine tumor is diagnosed, endocrinologists must be consider the
possibility of the existence of another endocrine tumor.
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Adrenocortical carcinomas (ACCs) are an extremely
rare type of cancer with an incidence of less than 2 per
1 million worldwide [1,2]. Approximately 60% of patients
present with symptoms of excess hormone secretion or
manifest themselves as symptoms and signs due to mass
effect. Thyroid cancer is the most common malignant
endocrine tumor. Its annual incidence varies between 0.5
to 10 per 100,000. Papillary thyroid carcinoma (PTC) is
the most common form of differentiated thyroid carcin-
oma and is more common in women than in men. It is
often diagnosed during investigation of a thyroid nodule
in clinics.
There are few case reports in the literature that describe
comorbid ACC and PTC. The available reports attribute
the concomitant appearance of the tumors to coincidence
and do not discount a potential genetic or hereditary link
[3-5]. Herein we report a rare coexistence of PTC and
ACC without clinical hormone excess.* Correspondence: meliakarakose@yahoo.com
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reproduction in any medium, provided the orCase presentation
A 40-year-old Turkish man who presented to our insti-
tution with shortness of breath was evaluated by com-
puted tomography. A mass in his left adrenal gland was
diagnosed incidentally. A magnetic resonance imaging
(MRI) scan showed a large mass measuring 8×9.5×10.4cm
in diameter in the left adrenal gland area (Figure 1).
His serum cortisol, adrenocorticotropic hormone, dehy-
droepiandrosterone sulfate, total testosterone, urinary
metanephrine, serum electrolytes (Na+, K+,Cl–), fasting
blood glucose, and fasting insulin levels were normal.
Plasma cortisol was suppressed after administration of
1mg dexamethasone. The patient was diagnosed with a
non-functional adrenal mass, and a left adrenalectomy
was performed. The resected tumor was 11×9×6cm in
size and weighed 339g. The tumor was of high nuclear
grade and had diffuse architecture, focal necrotic areas,
more than 5 mitoses per 50 high-power fields, and an
infiltrated capsule. Sinusoidal vascular infiltration was
observed, but clear cells were less than 25%. Immunohis-
tochemical studies showed that melan-A and inhibin were
positive, and thyroid transcription factor-1 (TTF-1) and
thyroglobulin were negative. The pathological findingsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Dynamic magnetic resonance imaging scans (left adrenal mass).
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radiotherapy with concurrent mitotane was planned for
the patient.
Evaluations of thyroid function tests were normal
before treatment and anti-thyroglobulin antibody was
positive, but anti-thyroperoxidase antibody was ne-
gative. Ultrasonographic evaluation of the thyroid re-
vealed the following: There was a nodule 3×4×4mm in
size in the lower part of the left lobe and foci of
microcalcification, and the edges were irregular and of
mixed echogenicity.
The elastosonography score of the nodule was 5, and
the strain index was calculated as 7.85 (Figure 2). The
patient had neither a history of radiation exposure nor a
family history positive for thyroid carcinoma. A fine-
needle aspiration biopsy of the nodule was suspicious
for malignancy. The patient underwent total thyroid-
ectomy and central neck dissection. Tumors were
detected in two foci with diameters of 0.9cm and 0.4cm
in the left lobe. There was neither lymphovascular nor
capsular invasion or lymph node metastasis. Immuno-
histochemical studies showed that thyroglobulin wasFigure 2 Elastosonographic and ultrasound images of the thyroid nopositive. The pathologic diagnosis was multicentric pa-
pillary thyroid microcarcinoma.Discussion
ACCs are a rare type of malignancy (incidence of 1 to 2
cases per 1 million population) with a heterogeneous
presentation and generally have a poor prognosis [1,6].
Women are affected more often than men [7,8]. The
diagnosis of malignancy of adrenocortical tumors de-
pend on careful investigations of clinical, biological, and
imaging features before surgery and pathological exam-
ination. The assessment of the Weiss score is important
for the diagnosis of malignancy [9,10]. Adrenocortical
tumors might be seen as a component of several heredi-
tary tumor syndromes such as Li-Fraumeni syndrome,
Beckwith-Wiedemann syndrome, multiple endocrine
neoplasia 1, Carney complex, and congenital adrenal
hyperplasia. A lot of specific genes might have a role in
the pathogenesis of sporadic ACC, and some of them
might be seen in the pathogenesis of the aforemen-
tioned syndromes [11,12].dule.
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hormone excess in approximately 60% of cases. Rapidly
progressing Cushing’s syndrome with or without vir-
ilization is the most frequent presentation. Hormonal in-
active ACC usually presents with abdominal discomfort
(nausea, vomiting, and abdominal fullness) or back pain
caused by a mass effect of the large tumor.
PTC comprises about 85% of cases with differentiated
thyroid carcinoma [13]. PTC usually presents with a thy-
roid nodule or cervical lymphadenopathy. Nodules more
than 1cm in diameter have a greater potential to be
malignant. On the other hand, patients with nodules less
than 1cm in diameter, suspicious ultrasound findings,
lymphadenopathy, a history of neck and head irradiation,
or a history of thyroid cancer in first-degree relatives
must be evaluated for cancer [14].
The ultrasonographic features suggesting the pres-
ence of malignancy in a thyroid nodule have been de-
scribed clearly. These include microcalcifications, marked
hypoechogenicity, absent “halo” sign, extraglandular ex-
tension, an irregular or microlobulated margin, and a het-
erogeneous echo structure [15,16]. Individual sonographic
features have limitations for prediction of thyroid cancer.
Elastosonography is a newly developed, promising sono-
graphic method for evaluating suspicious nodules. It gives
information about the stiffness of a nodule by measuring
the amount of distortion that occurs when the nodule is
subjected to external pressure [17]. Tissue stiffness is
scored from 1 to 5 based on subjective analysis of the
elastographic image. Rago et al. reported sensitivity of
97% and specificity of 100% for a score of 4 or 5 as being
predictive of malignancy [18].
PTC generally metastasizes to the lymph nodes. Distant
organ metastasis is rare, but lung, bone, brain, liver, and
adrenal gland metastases have been reported [19,20]. ACC
may metastasize to the thyroid gland [21]. Immunohisto-
chemical staining is used to differentiate the primary and
metastatic tumors. Melan-A, inhibin, and some other
markers have been found to be positive in patients with
ACC [22-24], and thyroglobulin and TTF-1 have been
found to be positive in patients with thyroid neoplasms in
immunohistochemical studies [25-28]. In our case, melan-
A and inhibin were positive, but thyroglobulin and TTF-1
were negative, in the patient’s adrenal gland tumor. The
thyroid lesion was thyroglobulin-positive. Therefore, these
lesions were evaluated as primary tumor neoplasms of
those organs.
In the literature, there are few case reports of patients
with with comorbid ACC and PTC. Fukushima et al.
reported a case of a middle-aged woman with virilizing
adrenocortical adenoma complicated with Cushing’s
syndrome, PTC, and hypergastrinemia [3]. They did not
study genetic analyses in their patient. Wanta et al.
reported the case of a patient with synchronouspresentation of an aldosterone-secreting metastatic
ACC and PTC [4]. That patient was diagnosed as having
Li-Fraumeni syndrome and multiple endocrine neopla-
sia type I, but both p53 and menin gene mutations were
absent.
Conclusion
Herein we present a case of a patient with PTC and
ACC without clinical hormone excess. Most ACCs and
PTCs are sporadic; however, the possibility of a heredi-
tary cancer syndrome could not be ruled out because of
the co-occurrence of two different endocrine neoplasms
within the same period of time. Therefore, when an
endocrine tumor is diagnosed in a patient, endocrinolo-
gists must consider the possibility of the existence of an-
other endocrine tumor.
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